MedPage Today) — SAN DIEGO — Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial confirmed.
In these patients…
Read More
